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In our WES series we found no significant increase in the burden of FAN1 mutations in cases (Table   1 ; Supplementary-Tables 2&3).
Germline mutation of TP53, archetypically associated with Li-Fraumeni syndrome, has recently been suggested to cause familial CRC at a frequency comparable to APC 7 . The assertion was, however, based on the flawed assumption that all rare missense changes seen were diseasecausing with no consideration of mutation burden in controls (Supplementary-Material, Supplementary- Table 1 ). In our data no over-representation of TP53 mutation was seen in cases (Table 1, Supplementary-Tables 2&3). By WES small numbers of early-onset CRC, BUB1, BUB3, LRP6 and PTPN12 have been proposed as CRC predisposition genes 1,2 . The published evidence to support assertions is minimal (Supplementary-Material, Supplementary- Table 1 ) with no evidence of segregation or LOH.
Moreover, of the two BUB1 mutation carriers, one also carried a MLH1 mutation which, unlike BUB1, segregated with colorectal tumors. Only for PTPN12 did the authors demonstrate an increase in the burden of mutation in cases versus controls (P=0.039; Supplementary-Material).
While we also observed an enrichment of missense PTPN12 mutation in our WES cases (P=0.039; Table 1 , Supplementary- Table 3 ), in light of the number of genes investigated, the evidence for a role in CRC predisposition remains weak.
In conclusion a role for NTHL1 as a bona fide CRC gene is supported by multiple lines of evidence.
While compelling, the assertion that mutation of RPS20 causes CRC remains to be established as this observation is based on a single family and the mechanism by which ribosomal proteins might predispose to CRC is unclear. In contrast, evidence to support other genes as risk factors is currently lacking.
Investigators must remember that private variants are common; of the 7,404,909 variants listed in ExAC, 54% are observed only once 10 , therefore novel variants should be considered benign until proved otherwise. A studies power to detect a statistically significant association with any rare variant is typically weak, therefore additional evidence must be considered including segregation of the genotype with disease in families, somatic mutation and functional studies with relevance to CRC biology. Critically, where multiple variants are considered within a gene, the burden of variation within controls must also be considered. Since the frequency of variants can be highly population-specific it is essential that controls used for comparison are well matched.
While there is a strong rationale for seeking to identify new CRC genes, well powered studies are required to mitigate against erroneous findings being asserted as causative and subsequently included in databases from which they are seldom deleted. The WES data we have generated represents the largest cohort of CRC exomes sequenced to date. The use of this dataset, which is publically available, to validate observations from small sequencing studies should act to limit the reporting of false positive results. Finally, the evidence framework we have implemented to assess the validity of proposed CRC genes, provides a robust strategy for establishing clinically actionable genes. 
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